The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Sumitomo Pharma

Status: Completed

Conditions: Schizophrenia

Treatments: Drug: Lurasidone HCl

Study type: Observational

Funder types: Industry

Identifiers

NCT04432688

DSPCLAT-001

Details and patient eligibility

About

It's a prospective, non-interventional, observational Post-marketing Surveillance..

Full description

It's a prospective, non-interventional, observational Post-marketing Surveillance, the aim of the surveillance is to observe the safety and overall effectiveness of Latuda® in the treatment of Chinese patients with schizophrenia for 12 weeks in real clinical practice, as well as the dose of Latuda® for monotherapy or combination therapy.

Enrollment: 3,192 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Schizophrenia Patients who begin to receive Latuda®

Exclusion criteria

• No exclusion criteria

Trial design

3,192 participants in 1 patient group

Latuda®

Description:

Chinese schizophrenia patients who are receiving Latuda® in the real world

Treatment:

Drug: Lurasidone HCl